VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2004 participants.

Also called NCT01528254

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,004 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01528254
  • EudraCT 2011-003712-23
Other papers using this trial's data
  • Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial Lancet (London, England), 2019-10-26 DOI, PubMed 31542292

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Argentina, Australia, Austria, Brazil, Bulgaria, Colombia, Czechia, Dominican Republic, Estonia, Finland, Germany, Guatemala, Hong Kong SAR China, Hungary, India, Israel, Italy, Latvia, Lithuania, Malaysia, Mexico, Norway, Panama, Peru, Philippines, Poland, Romania, Russia, Slovakia, South Africa, South Korea, Spain, Taiwan, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01528254. Randomized; quadruple masking; primary purpose treatment. Start 2012-03-30 (actual); primary completion 2019-04-04 (actual). Results posted on 2020-04-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo of vildagliptin
Intervention (Drug)
vildagliptin
Intervention (Drug)
Metformin
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01528254
Content hash
fe48c01e17e844997e45e19b968746f7a476bc35aee99074682e211c53a92913